Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
189.28
+1.69 (0.90%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 187.60 - 189.72
52 week 150.38 - 191.10
Open 188.36
Vol / Avg. 3.65M/2.68M
Mkt cap 137.40B
P/E 17.09
Div/yield 1.32/2.79
EPS 11.07
Shares 725.91M
Beta 1.36
Inst. own 82%
Feb 1, 2018
Q4 2017 Amgen Inc Earnings Call - 5:00PM EST - Add to calendar
Feb 1, 2018
Q4 2017 Amgen Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 9, 2018
Amgen Inc at JPMorgan Healthcare Conference - Webcast
Jan 9, 2018
Amgen Inc at JPMorgan Healthcare Conference - Q&A Session
Dec 9, 2017
Amgen Inc Investor Meeting at the American Society of Hematology Meeting - Webcast
Nov 30, 2017
Amgen Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - Webcast
Nov 29, 2017
Amgen Inc at Piper Jaffray Healthcare Conference - Webcast
Oct 25, 2017
Q3 2017 Amgen Inc Earnings Call - Webcast
Oct 25, 2017
Q3 2017 Amgen Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 35.01% 33.59%
Operating margin 42.25% 42.60%
EBITD margin - 51.79%
Return on average assets 10.14% 10.36%
Return on average equity 25.35% 26.65%
Employees 19,200 -
CDP Score - C

Address

1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
David W. Meline Executive Vice President, Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 62
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 60
Bio & Compensation  - Reuters
Esteban Santos Executive Vice President, Operations
Age: 49
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 55
Bio & Compensation  - Reuters
Jonathan P. Graham Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Lori A. Johnston Senior Vice President
Age: 52
Bio & Compensation  - Reuters
David A. Piacquad Senior Vice President - Business Development
Age: 60
Bio & Compensation  - Reuters